Affiliation:
1. IQVIA
2. Boehringer Ingelheim International GmbH
Abstract
Abstract
Purpose. Patients with metastatic colorectal cancer (mCRC) experience multiple symptoms and impacts affecting their health-related quality of life. However, there is limited data on self-reported experience of the most relevant and bothersome aspects of patients living with mCRC.Methods. Semi-structured interviews were conducted in patients with mCRC to identify and understand the signs, symptoms and impacts experienced. Patients were also asked to rate the level of bothersomeness for each concept reported on a scale ranging from 0 (“not bothersome at all”) to 10 (“extremely bothersome”). Verbatim transcripts were analysed following a thematic analysis approach. The most salient concepts were identified (i.e., reported by >50% of patients with a bothersome rating ≥5 out of 10).Results. Twenty-five patients (United States; age: 26 to 72 years old) were interviewed. Patients reported 58 signs and symptoms, amongst which 8 were considered salient: fatigue, nausea, neuropathy, diarrhoea, loss of appetite, constipation, weight loss, and abdominal pain; 35 impacts were identified and 7 were considered salient: reduced ability to work, interference with daily activities, impact on cognitive functioning, financial impact, sleep changes, impact on social life and walking difficulties. The concepts identified helped refine a literature-based disease conceptual model of patient experience with mCRC.Conclusions. The interviews provided insights into the most bothersome and salient signs, symptoms and impacts affecting the HRQoL of patients living with mCRC.Implications for cancer survivors. There is a need to improve clinical strategies for future clinical development and inform clinical practice decision-making for mCRC survivors.
Publisher
Research Square Platform LLC
Reference17 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
3. A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer;Levin-Sparenberg E;Gastroenterol Res,2020
4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER. 2021. https://seer.cancer.gov/index.html. Accessed 19 Feb 2021
5. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review;Biller LH;JAMA,2021